Helsinn Healthcare
Helsinn Healthcare, a Swiss-based pharmaceutical company, has established itself as a leader in the oncology and supportive care sectors since its founding in 1977. Headquartered in Lugano, Switzerland, Helsinn operates globally, with significant presence in Europe, North America, and Asia. The company is renowned for its innovative approach to developing high-quality products that enhance the quality of life for cancer patients, including its flagship anti-emetic treatments. With a strong commitment to research and development, Helsinn has achieved notable milestones, including strategic partnerships and a robust pipeline of therapies. Its dedication to patient-centric solutions and a focus on unmet medical needs have positioned Helsinn as a trusted name in the healthcare industry, recognised for its contributions to cancer care and supportive therapies.
DitchCarbon Score
How does Helsinn Healthcare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Helsinn Healthcare's score of 25 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Helsinn Healthcare's reported carbon emissions
In 2022, Helsinn Healthcare, headquartered in Switzerland (CH), reported total carbon emissions of approximately 3,607,000 kg CO2e. This figure includes 36,650 kg CO2e from Scope 1 emissions, primarily from company cars, and 300 kg CO2e from Scope 2 emissions related to electricity consumption. The majority of their emissions, about 3,601,000 kg CO2e, fall under Scope 3, which encompasses indirect emissions from sources such as business travel and employee commuting. Comparatively, in 2021, Helsinn's total emissions were around 3,370,000 kg CO2e, with Scope 1 emissions at 1,175,000 kg CO2e, Scope 2 emissions at 340,000 kg CO2e, and Scope 3 emissions at 1,855,000 kg CO2e. This indicates a significant increase in emissions in 2022, particularly in Scope 3 categories. Helsinn Healthcare has not publicly committed to specific reduction targets or initiatives, nor do they have any SBTi (Science Based Targets initiative) reduction targets in place. Their emissions data is not cascaded from any parent organization, indicating that the reported figures are solely from Helsinn Healthcare S.A. Overall, while Helsinn Healthcare has made strides in reporting their emissions, the lack of reduction commitments highlights an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 1,175,000 | 00,000 |
| Scope 2 | 340,000 | 000 |
| Scope 3 | 1,855,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Helsinn Healthcare is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
